STOCK TITAN

Cerus Corp. - CERS STOCK NEWS

Welcome to our dedicated news page for Cerus (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cerus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cerus's position in the market.

Rhea-AI Summary
Cerus (CERS) receives FDA approval for a 12-month shelf life extension for INTERCEPT Platelet Processing Sets, providing relief to customers and supply chains. The company aims to pursue further extensions beyond 12 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
fda approval
-
Rhea-AI Summary
Cerus (Nasdaq: CERS) announces positive results for ReCePI Phase 3 trial of INTERCEPT Red Blood Cells showing non-inferiority in acute kidney injury incidence compared to conventional RBCs. Safety data also favorable.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.68%
Tags
clinical trial
-
Rhea-AI Summary
Cerus Corporation (Nasdaq: CERS) reported sequential revenue growth in the fourth quarter driven by sales in North America, with a narrowed GAAP net loss. The company achieved its goal of adjusted EBITDA breakeven for the fourth quarter and reiterated its full-year 2024 product revenue guidance range of $172-175 million. Cash and cash equivalents were $65.9 million at the end of December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.61%
Tags
earnings
Rhea-AI Summary
Cerus Corporation (CERS) will release its fourth quarter and full-year 2023 financial results on March 5, 2024. A conference call and webcast will follow to discuss the financial results and provide a business outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
earnings
-
Rhea-AI Summary
Cerus Corporation (CERS) will have management participation in two upcoming investor conferences, the BTIG 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13th and TD Cowen’s 44th Annual Health Care Conference on March 6th. The company will also have a live webcast of the TD Cowen presentation, with a replay available on their website after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
conferences
-
Rhea-AI Summary
Cerus Corporation (CERS) announces preliminary fourth quarter and full-year 2023 product revenues of $46.8 million and $156.4 million, respectively. The company also provided product revenue guidance for full-year 2024, expecting revenues to be between $172-$175 million, reflecting 10%-12% growth year over year. The unaudited preliminary product revenue for the fourth quarter of 2023 showed a 6% increase over the same period in 2022, and a sequential increase of 18%. Cerus expects double-digit product revenue growth for full-year 2024, driven by continued growth in their INTERCEPT Platelet franchises in both the U.S. and internationally, as well as in the INTERCEPT Fibrinogen Complex business. The company also anticipates reaching adjusted EBITDA breakeven for the fourth quarter of 2023, which will be important for funding future growth. Additionally, Cerus anticipates a meaningful year for their INTERCEPT Red Blood Cell (RBC) program in 2024, with key catalysts for advancing the program towards commercialization expected in the first and second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
Rhea-AI Summary
Cerus Corporation (NASDAQ:CERS) will participate in two upcoming investor conferences. Cerus' president and CEO, William 'Obi' Greenman, will participate in a fireside chat at The Stifel 2023 Healthcare Conference on November 14th. Cerus' CFO, Kevin Green, will participate in a fireside chat at The Stephens Annual Investment Conference on November 15th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
conferences
-
Rhea-AI Summary
Cerus Corporation (Nasdaq: CERS) announced Q3 2023 financial results with total revenue of $47.3 million, consisting of $39.8 million in product revenue and $7.5 million in government contract revenue. The company completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients and expects top-line data readout in Q1 2024. Cash, cash equivalents, and short-term investments were $79.0 million at the end of September 2023. The company reaffirmed its commitment to achieve non-GAAP adjusted EBITDA breakeven in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.81%
Tags
earnings
-
Rhea-AI Summary
Healthcare software and services company Bloodbuy has entered into an agreement with Cerus Corporation to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) on its online marketplace. IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. The agreement aims to enhance patient outcomes and address inventory challenges in hospitals and blood centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
Rhea-AI Summary
Healthcare software and services company Bloodbuy has entered into an agreement with Cerus Corporation to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (IFC) on its online marketplace. IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life. The agreement aims to enhance patient outcomes and address inventory challenges in hospitals and blood centers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Cerus Corp.

Nasdaq:CERS

CERS Rankings

CERS Stock Data

324.50M
154.72M
3.76%
74.96%
2.48%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Concord

About CERS

cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.